Literature DB >> 26028026

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.

S J H Ricoult1, J L Yecies1, I Ben-Sahra1, B D Manning1.   

Abstract

An enhanced capacity for de novo lipid synthesis is a metabolic feature of most cancer cells that distinguishes them from their cells of origin. However, the mechanisms through which oncogenes alter lipid metabolism are poorly understood. We find that expression of oncogenic PI3K (H1047R) or K-Ras (G12V) in breast epithelial cells is sufficient to induce de novo lipogenesis, and this occurs through the convergent activation of the mechanistic target of rapamycin complex 1 (mTORC1) downstream of these common oncogenes. Oncogenic stimulation of mTORC1 signaling in this isogenic setting or a panel of eight breast cancer cell lines leads to activation of the sterol regulatory element-binding proteins (SREBP1 and SREBP2) that are required for oncogene-induced lipid synthesis. The SREBPs are also required for the growth factor-independent growth and proliferation of oncogene-expressing cells. Finally, we find that elevated mTORC1 signaling is associated with increased mRNA and protein levels of canonical SREBP targets in primary human breast cancer samples. These data suggest that the mTORC1/SREBP pathway is a major mechanism through which common oncogenic signaling events induce de novo lipid synthesis to promote aberrant growth and proliferation of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26028026      PMCID: PMC4666838          DOI: 10.1038/onc.2015.179

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

1.  Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.

Authors:  Urvashi V Roongta; Jonathan G Pabalan; Xinyu Wang; Rolf-Peter Ryseck; Joseph Fargnoli; Benjamin J Henley; Wen-Pin Yang; Jun Zhu; Malavi T Madireddi; R Michael Lawrence; Tai W Wong; Brent A Rupnow
Journal:  Mol Cancer Res       Date:  2011-09-27       Impact factor: 5.852

2.  Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment.

Authors:  J Sakai; E A Duncan; R B Rawson; X Hua; M S Brown; J L Goldstein
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.

Authors:  Jessica L Yecies; Hui H Zhang; Suchithra Menon; Sihao Liu; Derek Yecies; Alex I Lipovsky; Cem Gorgun; David J Kwiatkowski; Gökhan S Hotamisligil; Chih-Hao Lee; Brendan D Manning
Journal:  Cell Metab       Date:  2011-07-06       Impact factor: 27.287

4.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

5.  ATP citrate lyase inhibition can suppress tumor cell growth.

Authors:  Georgia Hatzivassiliou; Fangping Zhao; Daniel E Bauer; Charalambos Andreadis; Anthony N Shaw; Dashyant Dhanak; Sunil R Hingorani; David A Tuveson; Craig B Thompson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis.

Authors:  X Wang; R Sato; M S Brown; X Hua; J L Goldstein
Journal:  Cell       Date:  1994-04-08       Impact factor: 41.582

Review 7.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

8.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

9.  Inhibition of stearoyl-CoA desaturase 1 expression induces CHOP-dependent cell death in human cancer cells.

Authors:  Mélaine Minville-Walz; Anne-Sophie Pierre; Laurent Pichon; Sandrine Bellenger; Cécile Fèvre; Jérôme Bellenger; Christian Tessier; Michel Narce; Mickaël Rialland
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

10.  SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth.

Authors:  Thomas Porstmann; Claudio R Santos; Beatrice Griffiths; Megan Cully; Mary Wu; Sally Leevers; John R Griffiths; Yuen-Li Chung; Almut Schulze
Journal:  Cell Metab       Date:  2008-09       Impact factor: 27.287

View more
  86 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

2.  Ras Signaling in Breast Cancer.

Authors:  Aree Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.

Authors:  Stéphane J H Ricoult; Christian C Dibble; John M Asara; Brendan D Manning
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

Review 4.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

Review 5.  The Hippo pathway, p53 and cholesterol.

Authors:  Yael Aylon; Moshe Oren
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

Review 6.  The Heterogeneity of Lipid Metabolism in Cancer.

Authors:  Joshua K Park; Nathan J Coffey; Aaron Limoges; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 7.  SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology.

Authors:  Hitoshi Shimano; Ryuichiro Sato
Journal:  Nat Rev Endocrinol       Date:  2017-08-29       Impact factor: 43.330

8.  Emerging role of mTOR in the response to cancer therapeutics.

Authors:  Erika Ilagan; Brendan D Manning
Journal:  Trends Cancer       Date:  2016-05

9.  De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.

Authors:  Anju Singh; Christian Ruiz; Kavita Bhalla; John A Haley; Qing Kay Li; George Acquaah-Mensah; Emily Montal; Kuladeep R Sudini; Ferdinandos Skoulidis; Ignacio I Wistuba; Vassiliki Papadimitrakopoulou; John V Heymach; Laszlo G Boros; Edward Gabrielson; Julian Carretero; Kwok-Kin Wong; John D Haley; Shyam Biswal; Geoffrey D Girnun
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

Review 10.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.